Spotlight on the utility of the Oncotype DX® breast cancer assay
Zhen Rong Siow,1–3 Richard H De Boer,2,3 Geoffrey J Lindeman,1–4 G Bruce Mann2–4 1ACRF Stem Cells and Cancer Division, Walter and Eliza Hall Institute of Medical Research, 2Department of Medical Oncology, Peter MacCallum Cancer Centre, 3Familial Cancer Centre, The Royal Melbourne Hospital, 4Faculty...
Saved in:
Main Authors: | Siow ZR (Author), De Boer RH (Author), Lindeman GJ (Author), Mann GB (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2018-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer
by: Berdunov V, et al.
Published: (2022) -
Cost-effectiveness analysis of Mammostrat® compared with Oncotype DX® to inform the treatment of breast cancer
by: Mislick K, et al.
Published: (2014) -
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019) -
Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test from a US Societal Perspective
by: Berdunov V, et al.
Published: (2024) -
Multi-field-of-view strategy for image-based outcome prediction of multi-parametric estrogen receptor-positive breast cancer histopathology: Comparison to Oncotype DX
by: Ajay Basavanhally, et al.
Published: (2011)